Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass.
, Oct. 30, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a conference call and audio webcast at 8:00 a.
m. ET on Thursday, October 31, 2024 to provide a favorable study design update on the Company's pivotal Phase 3 SENTRY study in JAKi naive myelofibrosis. The call will feature leading myelofibrosis key opinion leaders Dr.
Raajit Rampal, Director of the Center for Hematologic Malignancies and Director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas, principal investigator of the Phase 3 SENTRY trial, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations .
An archived webcast will be available on the Company's website approximately two hours after the event. About Karyopharm Therapeutics Karyopharm Therapeutic.
